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Abstract
Alzheimer’s disease (AD) is a kind of neurodegenerative disease with insidious 
onset and progressive progression. The etiology of AD may be related to the loss 
of neurons, astrocytes, and microglial in the nervous system. Exogenous stem cell 
transplantation has brought hope to the treatment of AD. Stem cell transplantation 
can reduce amyloid β-protein (Aβ) deposition and Tau phosphorylation, and provide 
secretory factor support to improve learning and memory deficits. The purpose of 
this review is to provide an overview of the relationship between different stem cell 
species and the treatment of AD, and also summarize current experimental stem cell 
therapy strategies and their potential clinical applications in the future.
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1. Introduction
According to the World Alzheimer Report 2019, more than 50 million people 
worldwide suffer from dementia. It is expected to grow to 152 million by 2050. The 
current cost of treating dementia is $1 trillion a year, and that cost is expected to 
double by 2030. There are more than 200 subtypes of dementia, of which 50 to 60 
percent are caused by Alzheimer’s disease (AD). The concept of the disease was 
proposed by Alois Alzheimer in 1907. It was later recognized as the most common 
neurodegenerative disease. Although decades have passed since the discovery of the 
pathological mechanism of Alzheimer’s disease, we still do not know what causes 
the disease. It is well known that Alzheimer’s disease is a sporadic, age-related 
disease, with only a small proportion caused by genetic factors. The disease is char-
acterized by a progressive decline in cognitive function. Clinically, these patients 
present with short-term memory impairments that interfere with activities of daily 
living, followed by impairments in other cognitive areas such as language, logical 
understanding, orientation, executive function, judgment, behavior, and finally 
motor impairments [1]. The pathological features of AD include: Senile Plaques 
(SP) formed by the deposition of amyloid β-protein (Aβ) outside neurocyte; The 
abnormal phosphorylation of intracellular Tau protein results in the neurofibrillary 
tangles (NFTs); Synaptic loss, neuroinflammation, neurocyte apoptosis in the neo-
cortex and hippocampus of the brain. The pathological manifestations were brain 
atrophy [2–5]. In this review, we believe that the most effective strategies should 
target the biological feature which is most associated with symptoms, the loss of 
synapses, to treat the disease. Specifically, we focus on recent advances in cell-
based therapies that aim at repopulation or regeneration of degenerating neuronal 
networks in AD [6].
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2. Alzheimer’s Disease’s neuropathology
As mentioned in the background, we group the pathological changes of 
Alzheimer’s disease into two types, which provide evidence of the disease’s occur-
rence and progression: (1) Positive lesions. The main findings include SP caused 
by Aβ deposition and NFTs caused by abnormal phosphorylation of intracellular 
Tau protein. Otherwise, dystrophic neurites, neuropil threads and various other 
sediments found in the brains of patients with AD also falls into this category. (2) 
Negative lesions, which can also called loss type lesions. The main clinical mani-
festation is brain atrophy due to loss of synapses. At the same time, other factors, 
including neuroinflammation, oxidative stress, and damage to cholinergic neurons, 
are all important factors leading to the occurrence of neurodegenerative diseases.
2.1 Senile plaques (SP)
The SP are extracellular deposits of Aβ with different morphological forms, 
including neuritic, diffuse, dense-cored, or classic and compact type plaques [5].
The formation of Aβ is from the amyloidogenic cleavage of human amyloid 
precursor protein (APP) [7]. The anomalous processing of APP by β-secretases and 
γ-secretases leads to production of Aβ40 and Aβ42 monomers, which further oligo-
merize and aggregate into SP [8, 9]. Although soluble Aβ40 is much more abundant 
than soluble Aβ42, Aβ42 exhibits a higher propensity for aggregation, due to hydro-
phobicity within its two terminal residues. Indeed, Aβ42 is the main component 
of amyloid plaques and is shown to be neurotoxic [10]. Recent neuroimaging and 
neuropathology researches reveal that Aβ sedimentation is mainly related to cogni-
tive disorder of the old, and it is not very relevant with other clinical features [11].
2.2 Neurofibrillary tangles (NFTs)
Tau protein is mainly distributed in neurons. Repeated Pro-Gly-Gly-Gly frag-
ments help it bind to tubulin and maintain the structural stability of microtubules. 
The presence of Tau protein contributes to the maintenance of cytoskeleton and 
the integrity of axon transport [12]. NFTs are filamentous structures filled in the 
cytoplasm of neurons -- paired helical fibers (PHF). The reason of Tau hyper-
phosphorylation is the increased protein kinase activity. Protein kinase activity 
such as glycogen synthase kinase 3β (GSK-3β) activity can be decreased to reduce 
phosphorylation. Meanwhile, decreased phosphatase activity is also the reason of 
hyperphosphorylation. In addition, the lack of glucose in the brain can make Tau 
hyperphosphorylated by mediating the signal pathway of p38 mitogen-activated 
protein kinase (MAPK). Increasing the level of glucose in the brain may provide a 
new idea for treating AD, by using a pharmacological model of glucose deprivation 
and investigated its effect on Tau phosphorylation, synaptic function and cognition 
in a relevant transgenic mouse model of tauopathy, the h-Tau mouse [13]. It has 
been shown that phosphorylation of Tau protein at the early stage of AD inhibits Aβ 
toxicity, being that Tau phosphorylation-mediated by p38 MAPK can antagonize 
the postsynaptic excitation toxicity caused by Aβ [14, 15].
2.3 Synaptic loss
Soluble Aβ collaborate with pTau to induce synapse loss and cognitive impair-
ment in AD [16]. Metabolism of Aβ and Tau proteins is crucially influenced by 
autophagy. Autophagy is a lysosome-dependent, homeostatic process, in which 
organelles and proteins are degraded and recycled into energy [17]. Neuroplasticity 
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is an ongoing process that responds to the activity, injury, and death of neurons, 
including the regulation of the structure and function of axons, dendrites and 
synapses [18]. Overdeposition of Aβ and abnormal phosphorylation of Tau both 
lead to decreased neuroplasticity, which is manifested in a series of clinical symp-
toms caused by synaptic loss in AD [12, 19]. Aβ and Tau both trigger mitochondrial 
alterations. Some evidence suggests that mitochondrial perturbation acts as a key 
factor that is involved in synaptic failure and degeneration in AD [20]. Synaptic 
plasticity and long-term potentiation (LTP) are all about N-methyl-D-aspartate 
receptor (NMDAR). Aβ oligomer facilitates astrocytes (AS) to release glutamate by 
a7nAChR and activates NMDAR, making extracellular regulated protein kinases 
(ERK) signaling pathway to be suppressed and finally suppressing LTP, therefore 
the synaptic damages caused by NMDAR hyperactivation are the possible mecha-
nisms of AD occurring [21].
2.4 Neuroinflammation
The AD pathophysiology entails chronic inflammation involving innate immune 
cells including microglia, astrocytes, and other peripheral blood cells. Inflammatory 
mediators such as cytokines and complements are also linked to AD pathogenesis 
[22, 23]. Activation of microglia can induce the production of inflammasomes, 
which in turn increase inflammatory cytokines, and may eventually result in Aβ 
deposition [24, 25]. Studies have shown that after being activated, astrocytes 
will release the corresponding cytokines, which can lead to the enhancement of 
neuronal toxicity, as well as a decreased outgrowth of neuronal processes and an 
overall decreased activity rate [26]. Recent studies have shown that there is a direct 
interaction between microglia and astrocytes. In the form that once microglia are 
activated, they can lead to activation of astrocytes, thus forming feed-forward loops 
that are harmful to the surrounding environment [26]. The mechanism showed 
that when being activated, microglia release IL-1α, TNFα and C1q and astrocytes 
become activated. Microglia and astrocytes are major modulators of inflammation 
in the brain, and they are also the major sources of apolipoprotein E (ApoE) in the 
brain. ApoE is a multifunctional protein with central roles in lipid metabolism. 
It transports lipids, including cholesterol, through the cerebrospinal fluid (CSF) 
and plasma [27, 28]. Earlier studies have shown that the presence of ApoE helps 
to inhibit glial activation of lipopolysaccharides in glial cell culture experiments, 
suggesting that ApoE may exert a protective anti-inflammatory effect [29, 30]. 
Moreover, the exacerbated proinflammatory state that occurs during this period of 
AD can trigger the hyperphosphorylation of Tau. Several of the kinases responsible 
for Tau phosphorylation are activated by proinflammatory mediators and have been 
shown to worsen Tau pathology [31].
2.5 Cholinergic neurons’ injuries
The Acetylcholine (ACh) receptor (AChR) is a vital membrane protein on which 
ACh acts as a neurotransmitter. The cholinergic receptors are broadly categorized 
as muscarinic ACh receptors (mAChR) and nicotinic ACh receptors (nAChR) on 
the basis of their exogenous agonists [32]. ACh plays an important role in human 
memory function and is strongly associated with age-related dementia such as AD, 
in which hippocampal dependent learning dysfunction is prominent. Cholinergic 
neurons densely dominate the hippocampus and mediate the production of episodic 
and semantic memory [33]. In patients with AD, the synthesis, release and uptake 
of ACh in the hippocampus, neocortex and cerebrospinal fluid were decreased, the 
choline acetyltransferase (AChE) was significantly decreased, and the activity of 
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acetylcholinesterase was decreased [34]. Clinically, the main method of drug treat-
ment for AD is to improve the function of the brain’s cholinergic system. Although 
inhibitors of acetylcholinesterase is a symptomatic relief treatment with marginal 
benefits, it is currently the most available clinical treatment which gives desperate 
AD patients a glimmer of hope [35].
3. Stem cell therapy for AD
There are some theoretical approaches to treat early AD. One is to target upregu-
lation of resident neural stem cells (NSCs) niches within the adult brain. In fact, 
this regulation is to stimulate the development of adult hippocampal nerve, which 
has reached the purpose of compensating the degenerated nerve. Adult hippocam-
pal neurogenesis may play a key role in learning and memory, so promoting this 
endogenous process may help improve amnesia in patients with early AD. Another 
approach is to up-regulate growth factors that are known to modulate neurogenesis 
integrally, either through drug therapy or gene therapy or, as we describe in this 
paper, through stem cell therapy. This type of growth factor includes brain-derived 
neurotrophic factor (BDNF) [36, 37], insulin growth factor-1 (IGF-1) [38], nerve 
growth factor (NGF) [39–42], vascular endothelial growth factor (VEGF) [43, 
44] and so on. Stem cell therapy aims to rescue cognitive function by introducing 
exogenous stem cells to restore degenerated neural networks. These stem cells 
can be used as cell delivery systems through the natural or induced production of 
neuroprotective growth factors utilizing the paracrine “bystander” mechanism. 
Alternatively, therapeutic recovery may occur through the differentiation and 
involvement of stem cells in refilling degenerated neuronal circuits. It’s a finely 
balanced, complex, multi-step process.
Some of stem cells are now in clinical use, such as embryonic stem cells (ESCs) 
derived from the inner cell mass of preimplantation embryos and induced plu-
ripotent stem cells (iPSCs) derived from the epiblast layer of implanted embryos 
[45, 46]. Mesenchymal stem cells (MSCs) can promote tissue repair through the 
secretion of extracellular vesicles that carry a variety of cytokines, growth factors 
and microRNAs (miRNAs) [47]. Adipose tissue-derived stem cells (ADSCs) are 
a replacement therapy for MSCs, with the similar mechanism which secretion 
extracellular vesicles (EVs) to multiple proteins possessing neuroprotective and 
neurogenesis activities [48]. NSCs participate extensively in mammalian brain 
homeostasis and repair and exhibit pleiotropic intrinsic properties which makes 
them a good method for the treatment of AD [49].
3.1 ESCs
ESCs are cells isolated from early embryos or primitive gonads. It has the charac-
teristics of infinite proliferation, self-renewal and multidirectional differentiation 
in vitro culture. Both in vitro and in vivo, ESCs can be induced to differentiate into 
almost all cell types in the body, so they can be used to improve the recovery of 
neurodegenerative diseases (such as AD). Therefore ESCs have a broad application 
prospect in autologous stem cell therapy [50, 51]. Thymic epithelial progenitor cells 
derived from mouse ESCs with deleted amyloid precursor protein gene have been 
proved to have the ability to alleviate AD symptoms [52]. Early human embryonic 
stem cells (hESCs)-derived neural populations consist of various embryonic neural 
progenitors (ENPs) with broad neural developmental propensity. The hESC-ENP-
enriched neural transcription factors (TFs) can directly transform human cells 
into ENP phenotypes. Induced ENPs (IENPs) and their derivatives summarize the 
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signature pathological characteristics of AD and hold promise for future strategies 
for disease modeling and clinical intervention [53].
Although ESCs are good candidates for AD cell therapy, they may bring some 
ethical and practical problems. Even if we overcome the problem of immune rejec-
tion, there have been reports of teratomas resulting from transplanted ESCs [54].
3.2 NSCs
NSCs have the ability to differentiate into neuronal astrocytes and oligodendro-
cytes, which are self-renewing and sufficient to provide a large number of brain 
tissue cells [55, 56]. In the past, it was thought that NSCs lost their ability to regener-
ate during the prenatal period or several months after birth. However, some recent 
studies have shown that NSCs also exist in adult brain tissues, mainly located in the 
subventricular zone (SVZ) and hippocampus dentate gyrus (DG) [57–60]. Due to 
their multidirectional differentiation and self-renewal, NSCs play an important role in 
maintaining brain homeostasis, promoting normal nerve development and repairing 
damaged nerves, which provides a possible choice for stem cell therapy for AD [49, 61]. 
A large number of studies have shown that the gradual accumulation of Aβ leading to 
the loss of synapses related to cognitive deficits is an important mechanism of AD [62]. 
In the hippocampus of AD mice after NSCs transplantation, the level of Synaptophysin 
(SYP), postsynaptic density protein 95 (PSD-95) and microtubule-associated protein 
(MAP-2) were significantly increased, which are important protein markers related 
to synaptic plasticity and play an important role in synaptic plasticity and stability, 
indicating improved learning and memory ability in AD mice [63–65]. Damage of 
cholinergic neurons in the basal forebrain is another important feature of AD [66]. 
Reduced cholinergic function due to cholinergic neuron injury may results in learning 
and memory impairments [67]. Transplantation of NSCs into the basal forebrain will 
increase the level of choline acetyltransferase (ChAT) protein, restoring the damaged 
neurons and improving the learning and memory ability [68, 69].
Recent studies have demonstrated the mechanism of NSCs transplantation to 
improve cognitive function, which is replacing damaged neurons with the dif-
ferentiation of transplanted NSCs and enhancing synaptic density by releasing 
neurotrophic factors [61, 70, 71]. Neurotrophic factors have been shown to improve 
cognitive impairment [72, 73]. Although NSCs transplantation has great potential to 
be an excellent choice of cell therapy for AD in the future, there are many problems 
in its application: (1) The attribution that supports the differentiation of NSCs 
into a specific cell type is not clear. (2) Although NSCs transplantation can salvage 
synaptic damage and participate in the interaction of endogenous neuronal circuit 
function, there is no accurate answer to the duration of this effect. (3) The localiza-
tion of the transplanted area and the viability of the transplanted cells are only the 
initial challenges of NSCs therapy, and subsequent interactions with cells in the host 
environment are also important. In some studies, NSCs after transplantation is dif-
ficult to trace, and in the cases where NSCs can be traced, the number of activated 
cells is also difficult to quantify [74]. (4) Many studies have identified transplanted 
NSCs have potential risk of developing brain tumors, such as glioblastoma [75, 76]. 
(5) Extrinsic NSCs transplantation also involves ethical issues. Direct isolation of 
NSCs from the primary tissue is dangerous. Non-patient-specific NSCs are more 
likely to result in immune rejection [54, 77].
3.3 MSCs
MSCs are pluripotent stem cells, which have all the common features of stem 
cells, namely self-renewal and multidirectional differentiation. As major stem cells 
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that have undergone extensive clinical trials, MSCs bring hope for the treatment 
of a variety of diseases [78]. MSCs come from a wide range of sources. The most 
common ones are bone marrow mesenchymal stem cells (BMSCs), adipose-derived 
stem cells (ADSCs), umbilical cord derived mesenchymal stem cells (UC-MSCs), 
etc. Their biological characteristics are also different [79].
MSCs have the ability of immune regulation, neuroprotection and regenera-
tion. The main mechanisms of MSCs in the treatment of AD are as follows [80]: 
(1) Secrete growth factors: MSCs secrete a variety of pro-cytokines that may play 
a beneficial role in AD [81]. (2) Secrete exosomes: Exosomes refer to extracellular 
vesicles, which are biocompatible nanoparticles with lipid membranes. These 
vesicles can transmit messages across biological barriers. Studies have shown that 
intercellular exchange of miRNA and proteins through EVs can reduce neuroin-
flammation, promote neurogenesis and angiogenesis, save learning disabilities 
and improve functional recovery [82, 83]. (3) Reduce neuroinflammation by 
regulating autophagy: MSCs can affect the autophagy of immune cells involved 
in injury-induced inflammation, thereby reducing their survival, proliferation 
and function, and facilitating the regression of inflammation. In addition, MSCs 
can affect the autophagy of endogenous adult or progenitor cells, promote their 
survival, proliferation and differentiation, and support the recovery of functional 
tissues [84]. In addition, foreign proteins conveyed by MSCs can regulate microglia 
function and enhance neurogenesis, so as to alleviate early memory deficits in AD 
[85]. Transplantation of MSCs carrying CX3CL1 (a multifunctional inflammatory 
chemokine with a single receptor CX3CR1) [86] and Wnt3a (CX3CL1-Wnt3a-MSC) 
can regulate phosphoinositide 3-kinase/activated protein kinase B (PI3K/AKT) sig-
naling to inhibit the activity of glycogen synthase kinase 3 beta (GSK3β), improving 
the neurobehavioral function of mice by transplanting microglia with neurotoxicity 
and promoting hippocampal neurogenesis.
Reports have shown that EVs secreted by adipocytes derived from ADSCs may 
treat AD by alleviating neuronal damage, promoting neurogenesis and reducing the 
increase of neuronal apoptosis [48, 87]. EVs secreted by BMSCs can reach astro-
cytes to promote synaptic development and improve cognitive impairment [88, 89]. 
Hepatocyte growth factor (HGF), a core functional factor secreted by UC-MSCs, 
plays a key role in regulating the recovery of damaged nerve cells [90]. MSCs 
derived from ESCs have a better effect than BMSCs in the treatment of AD [91].
Modified MSCs pretreated with different conditions or reagents can signifi-
cantly enhance the therapeutic effect of AD and improve cognitive impairment, 
such as cytokine pretreated MSCs [92], hypoxia preconditioned MSCs (PCMSCs) 
[93], MSCs modified by lin28B [94], MSCs prepared by cerebrospinal fluid of AD 
patients [95], ADSCs pretreated by melatonin (MT) [96], UC-MSCs combined with 
resveratrol [97].
3.4 iPSCs
Using defined reprogramming factors to reprogram fully differentiated somatic 
cells into iPSCs has become a novel strategy to produce pluripotent cells derived from 
patients that enable autologous transplantation [98]. The apolipoprotein E4 (ApoE4) 
variant is the single greatest genetic risk factor for sporadic Alzheimer’s disease 
(sAD) [27–30]. sAD iPSCs convert ApoE4 to ApoE3 in brain cell types. This conver-
sion can reduce many AD-related diseases [99]. The generation of neural precursors 
from iPSCs has also been extensively studied. In the production of astrocytes, the 
mutation in presenilin1 (PSEN1) increased Aβ production and oxidative stress. At 
the same time, it also altered cytokine release and Ca2+ homeostasis. These changes 
reducing neuronal support function in PSEN1 astrocytes [100, 101]. EVs of either 
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50–200 nm in size (called exosomes) or 200 nm−1 μm in size (called micro-vesicles) 
are membrane-bounded vesicles. They can carry RNAs, proteins, and other metabo-
lites. They are secreted from all cell types and present in biological fluids such 
as serum and plasma [50, 102]. Human iPSCs can be cultured infinitely under a 
chemically defined medium. The properties and functions of exosomes and micro-
vesicles (called EMVs) from human iPSCs are different with the ones secreted by 
human MSCs. Purified EVs produced by both stem cell types have similar sizes, but 
human iPSCs produced 16-fold more EVs than MSCs [103]. Neurons from patients 
with early-onset familial Alzheimer’s disease (fAD) and patients with late-onset sAD 
showed increased phosphorylation of Tau protein at all investigated phosphorylation 
sites. Relative to the control neurons, neurons derived from patients with fAD and 
patients with sAD exhibited higher levels of extracellular amyloid-β 1–40 (Aβ1–40) 
and amyloid-β 1–42 (Aβ1–42) [104–106]. Using iPSCs-derived neurons to recapitulate 
AD pathology in vitro has significant applications in the study of pathogenesis and 
screening for potential therapeutic drugs. They are now the subject of extensive 
study in vitro [107]. Studies have also shown that EVs from iPSCs can play an impor-
tant role in heart repair [108].
3.5 Clinical trials and results in humans
Due to the inconsistent results of various preclinical studies, stem cell therapies 
other than MSCs are still difficult to be applied clinically. Some articles specifically 
showed us the application of MSCs-based stem cell therapy in human clinical trials 
[6, 80, 109, 110]. In recent years, more studies have been conducted on rodents. The 
effects of MSCs on AD pathology and cognitive mouse models may be mediated by 
the regulation of neuroinflammation [111, 112]. In recent years, clinical trials using 
mesenchymal stem cells have been conducted around the world. A completed clini-
cal trial in the United States (Trial identifier: NCT03117738) investigated the safety 
and efficacy of autologous ADSCs. At the same time, a team studied the efficacy 
of UC-MSCs (Trial identifier: NCT01297218). Compared with cholinergic drugs 
that only improve symptoms, UC-MSCs are immunologically stable and not-toxic, 
and have better therapeutic effect on AD. UC-MSCS remain a common cell choice, 
although there are key differences in cell number, dose quantity, and dose schedule 
(Trial identifier: NCT03172117). Two separate trials, both currently undergoing 
recruitment, will utilize alternative MSC sources. One studies human MSCs (Trial 
identifier: NCT02833792) and evaluates its safety and efficacy. The other utilizes 
the exosomes derived from allogenic adipose mesenchymal stem cells (MSCs-Exos) 
(Trial identifier: NCT04388982) to treat patients with mild to moderate dementia 
due to AD. While many of these trials employ an intravenous infusion administra-
tion route, one trial (Trial identifier: NCT03724136) administered BMSCs to the 
nasal mucosa topically, to investigate whether there was an improvement in efficacy 
in combination with intravenous injection.
4. Future directions
Numerous preclinical studies have revealed the different mechanisms of various 
stem cells and demonstrated the great potential of stem cells to treat AD. However, 
the biggest problem in this area of research is that it is difficult to translate animal 
studies into human trials. In fact, researchers have used nearly a hundred meth-
ods to effectively treat AD in transgenic mouse models. Disappointingly, almost 
every approach has failed in human clinical trials or has never even been tested in 
humans. Clearly, rodent models and their pathological assumptions are insufficient 
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to predict clinical outcomes in humans. Therefore, the establishment of more accu-
rate models is needed for cell therapy of AD. Since the goal of truly simulating the 
pathological progress of AD in human body has been achieved, more experiments 
on cell therapy need to be carried out.
At the same time, key questions remain to be addressed, including the safety of 
treatment, optimal cell source and delivery system. While cell therapies may not be 
able to fully compensate for the loss of extensive synapses, they can help to tem-
porarily improve existing depleted circuits enough to improve cognitive function, 
restore basic daily living functions, and improve quality of life. For us, stem cell 
therapy for AD still has a long way to go.
5. Conclusion
AD is a neurodegenerative disease, which is characterized by excessive depo-
sition of Aβ and abnormal phosphorylation of Tau protein and synaptic loss. 
Studies and clinical trials in recent years are also based on these basic mechanisms. 
Although the role of stem cell therapy in AD is not fully understood, many preclini-
cal studies have provided a number of promising results. However, human clinical 
trials are still in their infancy, and most current research is still centered on animal 
experiments. But it also shows the broad prospects of stem cell therapy for the AD. 
A large number of preclinical studies have demonstrated the theoretical basis, and 
new studies are continuing to reveal the underlying mechanisms. Among many 
stem cells, MSCs-based therapies are widely accepted and have met certain clinical 
trial standards. The vast majority of cell therapies for AD have been conducted 
on rodents, and we must be aware of a wide range of physiological differences 
between humans and rodents. We need to understand the mechanism of treatment 
through animal experiments and establish the correct translation model for human 
application.
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